No 02 2013
Updated: August 11, 2026, 09:41 am
Published: May 15, 2013
Top stories
Column – November 22, 2026
After three decades in the industry, I can conclude that decision-makers have a growing understanding of the strategic importance of Swedish life science. After all, this is where highly skilled jobs are created and the image of Sweden as an innovative nation is fostered, not to mention the economic surplus generated by life science exports.
Global report – November 20, 2026
Pfizer has signed an exclusive licensing deal with China-based Starna Therapeutics for three in vivo CAR-T programs targeting autoimmune diseases. Starna receives USD 330 million upfront and could earn up to USD 2.3 billion more in development and commercial milestones, plus royalties on net sales.
Business article – November 19, 2026
Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.
Collaboration – November 19, 2026
The Gates Foundation and NordForsk have signed a declaration to accelerate progress in women’s health by strengthening research, evidence, and innovation that can improve the lives of women and girls.
Related posts
This site uses cookies